Perceptive Inc., a specialist support provider for global pharmaceutical, biotech, and clinical research organizations, has announced it has secured $15.0 million in new investment capital. This funding round marks a significant milestone for the company as it looks to accelerate its strategic growth and expand its operational footprint. The investment underscores confidence in Perceptive's established expertise and its critical role within the life sciences sector.
Building on a combined 50-year history, Perceptive Inc. delivers best-in-class specialist support across the complete R&D lifecycle, from discovery and preclinical through clinical development to post marketing. Its comprehensive offerings include imaging biomarkers and core lab services, alongside innovative technologies in randomization and trial supply management (RTSM), analytics, and software. The company's services are designed to support the complex needs of its global clientele in the pharmaceutical, biotech, and clinical research sectors.
The $15.0 million in capital will be strategically deployed to enhance Perceptive Inc.'s technological platforms, broaden its service portfolio, and support its ongoing expansion into new markets. This funding is anticipated to strengthen Perceptive's capacity to meet the increasing demands of its global clientele by investing in key growth initiatives and operational improvements. The company aims to further solidify its position as a leading partner in pharmaceutical and biotech R&D.
Looking ahead, Perceptive Inc. is poised to leverage this capital injection to continue its trajectory of innovation and growth. The company remains committed to evolving its offerings to address the complex challenges faced by its clients worldwide, aiming to continuously enhance its specialized support and technological solutions for the life sciences industry.
.png&w=3840&q=75)
